Maryland SB435 regulates the sale and distribution of medetomidine and xylazine products, requiring proof of intended use and age verification.
Maryland SB435, the Medetomidine and Xylazine Consumer Protection Act, mandates that retailers cannot distribute, sell, or expose for sale medetomidine or xylazine products without proof of the purchaser's intent to use the product for institutional, veterinary, or scientific purposes. Retailers must also verify that purchasers are of legal age. Additionally, retailers must maintain records of all sales, including identification and proof of intended use.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.